ABSTRACT Background The ambulatory arterial stiffness index (AASI), derived from 24 h ambulatory blood pressure monitoring (ABPM) can be a good indicator of arterial stiffness. Aim To assess the correlation between AASI and brachial-ankle pulse wave velocity (baPWV), ankle-brachial index (ABI) and cardio-ankle vascular index (CAVI) in patients with type 2 diabetes mellitus without hypertension. Material and Methods Cross sectional study in 28 diabetic patients aged 49 ± 7 years (40% women). AASI was calculated as 1 minus the regression slope of diastolic on systolic blood pressure, using ABPM data. ABPM was measured in the arm using an oscillometric device. ABI was calculated as the ratio between ankle and brachial systolic blood pressure. CAVI was derived from pulse wave velocity using the Vasera VS-1000 device. Correlations were calculated using a bivariate Spearman correlation. Results The mean values for AASI, ABI, baPWV and CAVI were 0.39 ± 0.14, 1.14 ± 0.09, 15.15 ± 2.71 m/s and 7.60 ± 1.90, respectively. There was a significant negative correlation between AASI and ABI (r = -0.491, p < 0.01). Conclusions In these diabetic patients, there was an association between AASI, an arterial stiffness marker and ABI, an indicator for the presence of atherosclerosis.

Antecedentes El índice de rigidez arterial ambulatorio (AASI), derivado del monitoreo ambulatorio de presión arterial de 24 h (MAPA), puede ser un buen indicador de rigidez arterial. Objetivo Evaluar la correlación entre el AASI y la velocidad de onda de pulso braquial (VOP), el índice tobillo-brazo (ITB) y el índice vascular cardio-tobillo (CAVI) en pacientes con diabetes mellitus tipo 2 sin hipertensión arterial. Material y Métodos Estudio transversal en 28 pacientes con diabetes de 49 ± 7 años (40% mujeres). El AASI se calculó como 1 menos la pendiente de regresión de la presión arterial diastólica sobre la sistólica, usando datos del MAPA de 24 h, el cual se midió en el brazo, usando un dispositivo oscilométrico. El ITB se calculó como la razón entre la presión arterial sistólica del tobillo sobre la del brazo. El CAVI se derivó de la velocidad de onda de pulso medida con el dispositivo Vasera VS-1000. Para el análisis estadístico se utilizó el coeficiente de correlación bivariada de Spearman. Resultados Los valores de AASI, VOP, ITB y CAVI fueron 0.39 ± 0.14, 1.14 ± 0.09, 15.15 ± 2.71 m/s y 7.60 ± 1.90, respectivamente. Hubo una correlación negativa significativa entre AASI e ITB (r = -0.491, p < 0.01). Conclusiones Hay una asociación entre AASI, un marcador de rigidez arterial e ITB, un indicador de aterosclerosis, en estos pacientes con diabetes mellitus tipo 2.

Abstract Three diseases with a high prevalence in the adult population, especially in Mexico, are type 2 diabetes mellitus, arterial hypertension and hyperuricemia-gout; they share among them pathophysiological characteristics that favor their appearance as a group in the patients and whose treatments are frequently in the same way, the above-mentioned has allowed that in the following lines can be described such diseases as the three to;35(4):596-608. unfortunate enemies of the health of the population.

Resumen Tres enfermedades con alta prevalencia en la población adulta, especialmente en México, son la diabetes mellitus tipo 2, la hipertensión arterial y la hiperuricemia-gota; entre ellas comparten características fisiopatológicas que favorecen su aparición como Aceptado: 11 de junio 2019 un conjunto en los pacientes y cuyos tratamientos van frecuentemente de la mano, lo que ha permitido que en las siguientes líneas puedan describirse tales enfermedades Correspondencia como los tres desafortunados enemigos de la salud de la población. Manuel González Ortiz.

ABSTRACT Objective To evaluate the effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control. Materials and methods A randomized, double-blind, placebo-controlled clinical trial was carried out on 12 patients with T2DM and inadequate glycemic control [glycated hemoglobin A1c (A1C) ≥ 7%] with metformin as monotherapy (≥ 1500 mg per day) for at least the previous 90 days. Fasting and postprandial glucose were measured before and after the pharmacological intervention. A1C, lipid profile, creatinine and uric acid were also evaluated. After randomization, all patients continued with their dose of metformin. Six subjects received placebo and the other six volunteers took diacerein. Data were tested using the Wilcoxon signed-rank, Mann-Whitney U and chi-square tests. The Institutional Ethics Committee approved the study protocol. Results After 90 days of diacerein as an add-on to metformin, there was a significant decrease in fasting glucose (196 ± 79 vs. 149 ± 70 mg/dL, p < 0.05), postprandial glucose (262 ± 99 vs. 187 ± 70 mg/dlL, p < 0.05) and A1C (8.4 ± 2.0 vs. 6.7 ± 1.7 %, p < 0.05). Conclusions Diacerein as an add-on to metformin in patients with T2DM improved their glycemic control.

Background: Zinc is important for insulin synthesis, storage and secretion. When zinc concentration decrease, there is a concomitant reduction in insulin secretion and peripheral insulin sensitivity Aim: To assess the effects of zinc sulfate on insulin sensitivity, leptin and androgens in obese individuals. Material and methods: A randomized, double-blind, placebo-controlled clinical trial was performed in 14 obese volunteers between 21 and 30 years old, with body mass index (BMI) ³ 27 kg/m2. During one month, seven subjects received 100 mg/day of zinc sulfate orally (ZnG) and the other seven received placebo, as control group (CG). At baseline and after the intervention, insulin sensitivity was measured using a euglycemic-hyperinsulinemic clamp technique. Blood glucose, serum lipids, zinc, androgens and leptin were also measured in a fasting blood sample. Results: After the intervention, a rise in zinc concentrations from 11.8 to 16.9 umol/L; p=0.001 and in leptin levels from 15.2 to 27.7 ng/mL; p=0.029, was observed in the ZnG. No changes were observed in the CG. There were no significant changes in insulin sensitivity and androgens after the intervention with zinc sulfate. Conclusions: Zinc increased the leptin concentrations in obese individuals, but did not modify insulin sensitivity and androgens

El objetivo del presente estudio fue evaluar el efecto de un desayuno con alto contenido en grasa o en carbohidratos sobre el perfil de lípidos posprandial en individuos sanos con y sin el antecedente familiar en primera línea de diabetes mellitus tipo 2. Se realizó un ensayo clínico, ciego simple, controlado con grupos paralelos, en 20 jóvenes sanos; 10 con antecedente familiar de diabetes mellitus tipo 2 y 10 sin dicho antecedente. De cada grupo, la mitad de los individuos recibió al azar un desayuno con alto contenido en grasa y el resto uno alto en carbohidratos. Se determinó un perfil metabólico que incluyó medición de ayuno y posprandial de lípidos, así como estimación de la sensibilidad a la insulina. Se encontró una menor concentración del colesterol de las lipoproteínas de alta densidad (p < 0,02) y de apolipoproteína A1 (p < 0,03) en el grupo con antecedente familiar diabético. En ese mismo grupo, el desayuno con alto contenido en carbohidratos condicionó un aumento en las concentraciones de apolipoproteína B al minuto 300 (p <0,03) y de triglicéridos al minuto 360 (p < 0,03). En el grupo sin antecedente familiar de diabetes se encontró un aumento en la concentración de triglicéridos y de lipoproteínas de muy baja densidad al minuto 180 (p < 0,03) después del desayuno alto en grasa. En conclusión, los jóvenes sanos con el antecedente familiar de diabetes mellitus tipo 2 mostraron algunas características aterogénicas en su perfil de lípidos y un desayuno con alto contenido en carbohidratos ocasionó un aumento en la apolipoproteína B y en los triglicéridos; mientras que en los jóvenes sin el antecedente familiar fue la ingesta alta en grasa la que condicionó efectos desfavorables en los lípidos.

Effect of a high fat or high carbohydrate breakfast on postprandial lipid profile in healthy subjects with or without family history of type 2 diabetes mellitus. The objective of this study was to evaluate the effect of a high fat or high carbohydrate breakfast on postprandial lipid profile in healthy subjects with or without family history of type 2 diabetes mellitus. A single blind, controlled clinical trial with parallel groups was performed in 20 healthy subjects; 10 subjects with family history of type 2 diabetes mellitus and 10 individuals without that background. Each group was randomized to receive a high fat or high carbohidrate breakfast. A metabolic profile that included fasting and postprandial lipids, as well as, the assessment of insulin sensitivity were performed. Lower high-lipoprotein cholesterol (p < 0,02) and apolipoprotein A1 (p < 0,03) concentrations were found in subjects with family history of type 2 diabetes mellitus than those without that background. In this same above mentioned group with the high carbohydrate breakfast, there were significant increments in apoliprotein B at minute 300 (p < 0,03) and in triglycerides at minute 360 (p < 0,03). In the group without family history of diabetes that received the high fat breakfast, there were increments in triglycerides (p < 0,03) and very-low density lipoprotein concentrations at minute 180 (p < 0,03). In conclusion, healthy subjects with family history of type 2 diabetes showed some atherogenic characteristics in their metabolic profile, and the high carbohydrate breakfast produced in them increments in apolipoprotein B and in triglycerides, meanwhile that, in those subjects without such background the high fast breakfast produced unfavorable effects on their lipid concentrations.

Background: Inulin is a non absorbable polysaccharide with prebiotic effects, whose influence on blood lipids or insulin sensitivity is not well known. Aim: To assess the effect of oral administration of inulin on lipid profile and insulin sensitivity in dyslipidemic obese subjects. Material and Methods: A clinical trial, double blind, randomized with placebo was carried out in 12 obese, hypertrygliceridemic and hypercholesterolemic subjects between 19 and 32 years old. The subjects were randomized to receive 7 g/day of inulin or placebo in the morning, during 4 weeks. Biochemical and metabolic profiles and euglycemic-hyperinsulinemic clamp technique for assessing insulin sensitivity, before and after pharmacological intervention were performed. Results: After inulin administration, there was a significant reduction of total cholesterol (248.7±30.5 and 194.3±39.8 mg/dL; p=0.028), low density lipoprotein (LDL), cholesterol (136.0±27.8 and 113.0±36.2 mg/dL; p= 0.028), very low density lipoproteins (VLDL) (45.9±18.5 and 31.6±7.2 mg/dL; p=0.046) and trygliceride concentrations (235.5±85.9 and 171.1±37.9 mg/dL; p=0.046). No effect of inulin on insulin sensitivity was observed. Conclusions: The oral inulin administration reduced total cholesterol, LDL cholesterol, VLDL and trygliceride levels in dyslipidemic and obese subjects, without modifications in the insulin sensitivity. (Rev Méd Chile 2003; 131: 597-604)

This longitudinal prospective study was designed to assess the effects of the angiotensin converting enzyme inhibitor (ACEI) ramipril on ventricular mass, left ventricle (LV) diastolic function and blood pressure in patients with mild to moderate essential hypertension and hyperinsulinemia. LV diastolic dysfunction is the first target organ alteration occurring in hypertensive patients, while ventricular hypertrophy is the most relevant predictive factor for cardiovascular morbility and mortality in systemic hypertension. Because several studies have demonstrated that there is no direct correlation between blood pressure values and the severity of LV hypertrophy or diastolic dysfunction, it is assumed that other factors are involved in the genesis of these functional alterations. Moreover, the hypertensive effect of insulin is caused by sympathetic stimulation, sodium and water renal retention and protooncogene stimulation leading to myocardial and vascular fibrosis and hypertrophy. We studied 24 hypertensive patients with hyperinsulinemia. All patients underwent an overall and cardiologic clinical evaluation, and electrocardiographic and ecocardiographic studies were performed at baseline and 6 months after being treated with 2.5 to 5 mg/day ramipril. Ramipril treatment significantly reduced systolic (12 mmHg) and diastolic (12 mmHg) pressure levels, basal insulin serum levels (23.62 pmol/dL vs 10.42 pmol/dL), and left ventricle mass index values (143.8 g/m² vs 118.2 g/m²). Among the variables assessing LV diastolic function, only the transmitral flow E/ A wave ratio showed significant differences in women. Ramipril was well tolerated and no significant adverse events were reported. (Arch Cardiol Mex 2003; 73:24-30)

Este estudio longitudinal, prospectivo se diseñó para evaluar el efecto del ramipril, un inhibidor de la enzima convertidora de angiotensina (IECA) sobre la masa ventricular, la función diastólica del ventrículo izquierdo (VI) y los valores de tensión arterial en pacientes con hipertensión arterial sistémica esencial (HAS) leve a moderada con hiperinsulinemia. La primera alteración del paciente hipertenso es la disfunción diastólica del VI y el dato de mayor peso como factor predictor de morbimortalidad cardiovascular en la HAS es la hipertrofia ventricular. Existen múltiples estudios que demuestran que no existe una correlación directa entre los valores de tensión arterial y el grado de hipertrofia o disfunción diastólica del ventrículo izquierdo, motivo por el cual se asume la participación de otros factores en la génesis de estas alteraciones funcionales. Por otra parte, está descrito que la insulina posee efectos hipertensores por estimulación simpática, por retener sodio y agua a nivel renal y por estimular la expresión de protooncogenes con el subsecuente desarrollo de fibrosis e hipertrofia miocárdica y vascular. A pesar de que existe en el mercado una gran cantidad de fármacos antihipertensivos, algunos de ellos producen efectos metabólicos adversos, mientras que otros como los inhibidores de la enzima convertidora de angiotensina (IECAS), los ARAII y los bloqueadores del calcio además de controlar los niveles de presión arterial tienen un efecto neutro o benéfico sobre dichos parámetros. Considerando el efecto de los IECAS sobre el perfil metabólico, se realizó un estudio con 24 pacientes hipertensos esenciales con hiperinsulinemia, a los cuales se les realizó evaluación clínica cardiológica y general, electrocardiograma y ecocardiograma en condiciones basales y después de 6 meses de tratamiento con ramipril a dosis de 2.5 a 5 mg/día. Los resultados muestran una reducción significativa de la tensión arterial sistólica (12 mmHg) y diastólica (12 mmHg), de los niveles séricos de insulina basal (23.62 pmol/dL vs 10.42 pmol/dL), y del índice de masa ventricular izquierda (143.8 g/m² vs 118.2 g/m²). En las variables que evalúan la función diastólica del VI no hubo diferencias estadísticamente significativas a excepción de la relación onda E/onda A del flujo transmitral en el grupo de mujeres. Ramipril fue bien tolerado y no se reportaron eventos adversos significativos.

The cardiovascular protective properties of hormone replacement therapy can be hampered when a progestin is used. Aim: To assess the effects of hormone replacement therapy with progestins on insulin sensitivity and lipid profile. Patients and methods: Twelve healthy postmenopausal women aged 45 to 55 years old were studied. Blood lipids and insulin sensitivity, determined using the insulin tolerance test, were measured at baseline and after three months of hormone replacement therapy using conjugated estrogens, 0.625 mg/day and medroxyprogesterone acetate, 5 mg/day. Results: The glucose disappearance constant was higher after the treatment period than at baseline (5.3±0.8 and 4.7±0.8%/min respectively, p = 0.005). Serum LDL cholesterol was also lower at the end of treatment period (124.5 ± 30.2 and 140±25.4 mg/dl respectively, p = 0.019). Conclusions: In this group of postmenopausal women, a period of three months of hormone replacement therapy with a progestin improved insulin sensitivity and lowered LDL cholesterol levels (Rev Méd Chile 2001; 129: 989-94)

Background: Serum leptin levels increase during pregnancy and this increase is more pronounced in women with preemclapsia. Aim: To determine if there is a significant correlation of serum leptin with insulin and glucose levels in normotensive pregnant women and in preeclampsia patients. Material and methods: A nested case-control study in 16 normotensive pregnant women and in 16 preeclampsia mestizo Mexicans in the third trimester of the gestation, matched by age, gestational age and pre gestational body mass index. Venous blood samples after at least 6 h fast, were obtained and stored at -70 °C to measure serum leptin levels by ELISA, insulin concentrations by RIA and glucose by the glucose oxidase technique. Results: There were no differences between normotensive women and those with preeclampsia in serum leptin, insulin and glucose levels. There was a positive correlation between leptin and insulin concentrations (p=0.005), a negative correlation between leptin and glucose levels (p=0.02) and no correlation between leptin and pre gestational body mass index. Conclusions: In this study, women with preeclampsia did not have higher leptin levels than normotensive pregnant women (Rev Méd Chile 2001; 129: 149-54).